Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 3:13:4.
doi: 10.1186/1758-2652-13-4.

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy

Philippa J Easterbrook  1 , Mel Smith, Jane Mullen, Siobhan O'Shea, Ian Chrystie, Annemiek de Ruiter, Iain D Tatt, Anna Maria Geretti, Mark Zuckerman
Affiliations

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy

Philippa J Easterbrook et al. J Int AIDS Soc. .

Abstract

Background: Our intention was to compare the rate of immunological progression prior to antiretroviral therapy (ART) and the virological response to ART in patients infected with subtype B and four non-B HIV-1 subtypes (A, C, D and the circulating recombinant form, CRF02-AG) in an ethnically diverse population of HIV-1-infected patients in south London.

Methods: A random sample of 861 HIV-1-infected patients attending HIV clinics at King's and St Thomas' hospitals' were subtyped using an in-house enzyme-linked immunoassay and env sequencing. Subtypes were compared on the rate of CD4 cell decline using a multi-level random effects model. Virological response to ART was compared using the time to virological suppression (< 400 copies/ml) and rate of virological rebound (> 400 copies/ml) following initial suppression.

Results: Complete subtype and epidemiological data were available for 679 patients, of whom 357 (52.6%) were white and 230 (33.9%) were black African. Subtype B (n = 394) accounted for the majority of infections, followed by subtypes C (n = 125), A (n = 84), D (n = 51) and CRF02-AG (n = 25). There were no significant differences in rate of CD4 cell decline, initial response to highly active antiretroviral therapy and subsequent rate of virological rebound for subtypes B, A, C and CRF02-AG. However, a statistically significant four-fold faster rate of CD4 decline (after adjustment for gender, ethnicity and baseline CD4 count) was observed for subtype D. In addition, subtype D infections showed a higher rate of virological rebound at six months (70%) compared with subtypes B (45%, p = 0.02), A (35%, p = 0.004) and C (34%, p = 0.01)

Conclusions: This is the first study from an industrialized country to show a faster CD4 cell decline and higher rate of subsequent virological failure with subtype D infection. Further studies are needed to identify the molecular mechanisms responsible for the greater virulence of subtype D.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time to virological suppression < 400 copies/ml following initiation of HAART according to subtype.
Figure 2
Figure 2
Time to virological rebound following initial viral load suppression < 400 copies/ml according to subtype.
See this image and copyright information in PMC

References

    1. Osmanov S, Pattou C, Walker N, Schwärdlander B, Esparza J. WHO-UNAIDS Network for HIV Isolation and Characterization: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr. 2002;13:184–190. - PubMed
    1. Thomson MM, Pérez-Álvarez L, Nájera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2002;13:461–471. doi: 10.1016/S1473-3099(02)00343-2. - DOI - PubMed
    1. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis. 2006;13(1):1–7. doi: 10.1097/01.qco.0000200293.45532.68. - DOI - PubMed
    1. Fleury H, Recordon-Pinson P, Caumont A, Faure M, Roques P, Plantier JC, Couturier E, Dormont D, Masquelier B, Simon F. Agence Nationale de Recherche sur le SIDA AC11 Laboratory Network. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res and Hum Retrovir. 2003;13:41–47. doi: 10.1089/08892220360473952. - DOI - PubMed
    1. Snoeck J, Van Laethem K, Hermans P, Van Wijngaerden E, Derdelinckx I, Schrooten Y, Vijver DA van de, De Wit S, Clumeck N, Vandamme AM. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr. 2004;13:279–285. doi: 10.1097/00126334-200403010-00009. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources